COLL: Collegium Pharmaceutical, Inc. - Summary | Jitta

Collegium Pharmaceutical, Inc.

NASDAQ:COLL

Price
$28.59
Loss Chance
43.8%
4.51JITTA SCORE
75.73%Under Jitta Line
Jitta Ranking
4 / 1,189
177 / 4,969
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (66)
Recent Business Performance (57)
Financial Strength (55)
Return to Shareholders (37)
Competitive Advantage (52)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
SG&A to SalesDecreasing
Revenue and EarningEarning loss detected in 2019
Operating MarginDeclined
Key Stats
Jitta Score
Jitta Line
4.51
75.73%
1.94
293.46%
2.00
228.80%
Pharmaceuticals
6.67
35.50%
3.58
62.87%
6.48
4.20%
COMPANY DESCRIPTION
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.